Background/Aim: Ulcerative colitis (UC) is a chronic, relapsing inflammatory disease affecting distal colon and rectum with complex pathogenesis and diagnosis, indicating on need for new diagnostic and prognostic markers. The aim of study was to determine fecal values of TNF-α, IL-17, IL-10 and sST2 in patients with UC and the relationship with clinicopathological aspects. Methods: The samples of stool of 80 patients with UC were analyzed. Concentrations of TNF-α, IL-17, IL-10 and sST2 were measured by ELISA. Results: Concentrations of TNF-α, IL-17 and sST2 were significantly increased in feces of patients with higher endoscopic, clinical and total Mayo score, as well as in patients with intense crypt destruction, erosion of the mucous membranes, architectural changes, neutrophil infiltration and eosinophil infiltration. Local value of anti-inflammatory cytokine IL-10 in liquid fraction of feces was increased in patients with advanced endoscopic stage of UC. Moderate positive correlation between fecal sST2/IL-17 and clinical and histological parameters of disease severity and also strong correlation between sST2 and IL-17 was also observed in feces of patients with UC. Analysis of Receiver
and Crohn`s disease (CD). Ulcerative colitis (UC) is a chronic, relapsing inflammatory disease affecting distal colon and rectum, limited to the mucosa and associated with continuous, submucosal inflammation and the formation of ulcers (1) (2) . The pathogenesis of disease is complex. Immune system seems to be major mediator in it (3). It`s usually based on imbalance between pro-and anti-inflammatory cytokines in the intestinal mucosa and subsequent chronic inflammation (4) (5) . The secretion of type 1 (TNF-α, IFN-γ), type 2 (IL-4, IL-10) and type 17 cytokines (IL-17) as well as response to self antigens in mucosa are predominant factors in genesis and development of UC (6) (7) (8) (9) . Although UC seems to be predominantly Th2 disease (10) , recent data revealed important role of type 1 and type 17 innate and acquired immune responses in onset and progression of disease (11) . Local chronic inflammation, typical for UC, often leads to clinical symptoms and signs such as diarrhea, rectal bleeding, abdominal pain, fever, anemia and body weight loss (2) . Disease activity can be determinate using clinical and endoscopic scores, serum or fecal biomarkers (12) (13) (14) . Endoscopic findings of mucosa become among the major parameters in estimating disease severity (13) (14) (15) . Disadvantage of using clinical and endoscopic scores for evaluation of disease severity is usage of invasive and costly procedures (15) . This has led to the need for noninvasive tests for disease evaluation. There has been a sustained interest in the identification of state bio-markers for UC severity (11, 15) . New markers should contribute to the prediction of prognosis.
The aim of the study was to compare the accuracy of selected biomarkers in assessing disease severity. Concentrations of biomarkers TNF-α, IL-17, IL-10 and sST2 were assessed in the stool samples of patients with UC. We tested how reliable these biomarkers reflect clinical and endoscopic scores and histopathological characteristics of affected tissue. For more sensitive markers, we determined cutoff levels for clinically and endoscopically estimated severe disease.
METHODS

Ethic approvals
The study was conducted at Center for Gastroenterology, Clinical 
Patients
Eighty patients, between 21 and 80 years of age diagnosed as UC cases were recruited in this study. Diagnosis was made on basis of established clinical, endoscopic and histological criteria (16) . The study did not include patients with no well-defined pathology, no adequate clinical document available or with previously diagnosed coexisting cardiopulmonary, renal, hepatic, allergy and rheumatic disease who were treated with antiinflammatory drugs. Stool samples were taken before the surgery and stored at -80°C.
Disease activity index
Clinical activity of disease was evaluated according to data available in patient records.
Three clinical variables were graded: frequency of evacuation, amount of blood in stool, and the physician's global assessment. A Mayo clinical subscore 0 was defined as remission, 1-3 as mildly active disease (I), 4-6 as moderately active disease (II), and ≥7 as severely active disease (III) (17) . Endoscopic findings were scored according to the Mayo endoscopic subscore, graded as normal (0), mild (I), moderate (II), or severe (III) disease activity. Finally, the full Mayo Score was calculated on basis of four parameters: stool frequency, rectal bleeding, endoscopic evaluation and Physician's global assessment (18) . Score 0-I was defined as remission and score II-III as active disease (19) .
Histological activity
Histological activity was scored according to Geboes Score (GS), considering presence of architectural changes, neutrophils, eosinophils, crypt destruction and erosion of the mucous membranes (20) .
Measurement of TNF-α, IL-17, IL-10 and sST2 in feces
Stools (1-10 g) were collected in sterile containers and weighed. They were divided into 1 g aliquots and then emulsified in 5 mL of protease inhibitor cocktail (SIGMA, P83401), diluted 1:100, and centrifuged for 5 minutes at 400 G, at 4˚C, as previously described (21, 22) . The supernatant fluid was collected and stored at -80°C until ELISA.
Fecal concentrations of cytokines were measured, as described (9) 
Statistical analysis
The statistical analyses were performed using SPSS 20.0 software. The results were reported as mean and standard error (SE). Statistically significant difference between the means of two groups was determined using Student's t-test for independent samples if the data had normal distribution or Mann-Whitney U-test for data without normal distribution.
Pearson's correlation evaluated the possible relationship between the cytokines and disease severity and progression in patients with CRC. Strength of correlation was defined as negative or positive weak (-0.3 to -0.1 or 0.1 to 0.3), moderate (-0.5 to -0.3 or 0.3 to 0.5) or strong (-1.0 to -0.5 or 1.0 to 0.5). P-value of 0.05 was considered as statistically significant.
RESULTS
Eighty patients, between 21 and 80 years of age diagnosed and histologically confirmed as UC were recruited in this study. There was no significant difference in gender distribution.
Clinical and pathologic characteristics of these patients are presented in Table 1 . We have assessed concentration of pro and anti-inflammatory cytokines as well as sST2 in fecal liquid fraction of all patients. Patients with UC were classified in two groups based on endoscopic, clinical and total Mayo score, respectively: I: scores 0 and 1; II: scores 2 and 3.
Representative images of endoscopic Mayo subscores of patients with ulcerative colitis are shown in Figure 1 . Further patients were divided according to histological characteristics (crypt destruction, erosion of the mucous membranes, architectural changes, neutrophil infiltration and eosinophil infiltration) into two groups: I: scores 0 and 1; II: scores 2 and 3.
We analyzed values of previously defined markers of interest between defined groups.
Fecal concentrations of TNF-α, IL-17 and IL-10 are associated with clinical activity, endoscopic and histo-pathologic characteristics of UC
Our evaluation revealed significantly higher level of TNF-α in group of patients with advanced endoscopic, clinical as well as total Mayo score (p<0.05; Figure 2A ). We also noticed significant increment of fecal level of TNF-α in group of patients with intense crypt destruction, erosion of the mucous membranes, architectural changes, neutrophil infiltration and eosinophil infiltration (p<0.05; Figure 2B ).
Patients with advanced endoscopic, clinical and total Mayo score revealed significantly higher IL-17 in feces in comparison to patients with lower endoscopic and clinical scores (p<0.05; Figure 3A ). IL-17 was higher in stool of patients with intense crypt destruction, erosion of the mucous membranes, architectural changes, neutrophil infiltration and eosinophil infiltration (p<0.05; Figure 3B ). Figure 4 , UC patients with higher endoscopic, clinical and total Mayo score appear to have higher fecal level of IL-10, although this difference reached statistical significance for endoscopic score only (p=0.006).
As shown in
Clinical activity, endoscopic and histo-pathologic characteristics of UC are associated with higher fecal sST2
We noticed higher fecal level of sST2 in patients with advanced endoscopic, clinical and total Mayo score (p<0.05; Figure 5A ). Further, sST2 was significantly increased in patients with strong crypt destruction, erosion of the mucous membranes, architectural changes, neutrophil infiltration and eosinophil infiltration (p<0.05; Figure 5B ). Analysis of Receiver Operating Characteristic (ROC) curves of fecal sST2 for various stages and parameters of UC found that sST2 level in feces could predict disease severity. Analysis showed that sST2 can be a valuable marker for distinguishing clinical score (sensitivity 77,8%, specificity 66,7%) and total Mayo score (sensitivity 79,2%, specificity 61,9%). The optimal cut off value estimated for sST2 that allows the discrimination of stages of UC progression was 624,0 pg/g.
Fecal sST2 and IL-17 concentrations significantly correlated with disease severity
The relationship between fecal sST2/IL-17 and the clinico-pathological parameters of patients with UC were summarized in Table 2 . Analysis revealed positive correlation between fecal sST2/IL-17 and parameters and markers of disease severity. There is moderate positive correlation between fecal sST2/IL- 17 p=0.038 r=0.305; p=0.028). Finally, we found strong positive correlation between fecal sST2 and IL-17 (r=0.771; p=0.001).
DISCUSSION
Recently, studies have pointed on significance of measuring biomarkers in feces (23) (24) (25) (26) (27) .
These kinds of tests have significant promise. In this way, proteins and molecules produced by intestinal mucosa are measured, which reflects intestinal inflammation (27) . Recent studies have considered the potential as well as diagnostic accuracy of different noninvasive fecal markers in the detection of IBD and as indicators of the therapy response (23) (24) (25) (26) (27) .
Our results revealed that levels of all measured biomarkers in feces reflected disease activity. Domination of type 1 response, manifested by significantly higher fecal level of TNF-α was detected in patients with advanced endoscopic score, higher clinical and total Mayo score and intense cript destruction, erosion of the mucous membranes, architectural changes, neutrophil and eosinophil infiltration, respectively ( Figure 2 ). This indicates that TNF-α correlates with the severity of the UC. TNF-α is already established as master cytokine implicated in the pathogenesis of various inflammatory conditions, particularly IBD (28, 29) . Its importance has been confirmed in many studies using anti-TNF antibodies in controlling disease activity (30, 31) . The main sources of TNF-α are activated macrophages and Th1 cells (32, 33) . Elevated level of TNF-α in sera, stool or intestinal tissue were detected in UC patients (34, 35) , while systemic values of TNF-α correlate with clinical activity of UC (36) .
Current publications indicate that type 17 immune response also play important role in the biology of UC (37, 38) . Type 17 response is mediated mainly by IL-17, produced by Th-17 cells and CD8 + T cells, during chronic inflammation (39) . Our data revealed significantly increased fecal level of IL-17 in patients with more severe stage of UC (advanced endoscopic and clinical score and histological grade; Figure 3 ). We also obtained positive correlation between fecal IL-17 and disease severity (advanced endoscopic score, higher clinical and total Mayo score; Table 2 ). Moreover, fecal level of IL-17 is in positive correlation with histologically advanced and more severe disease (intense cript destruction, erosion of the mucous membranes, architectural changes, neutrophil and eosinophil infiltration, respectively; Table 2 ). Although many studies support pro-inflammatory role of IL-17 in genesis and progression of UC (38, 40) , some demonstrated a protective role of IL-17 in IBD (41) . IL-17 can mediate protective function in experimental model of UC (42) . In humans, recent publications showed that IL-17 levels were increased in UC patients, and correlated with disease severity (37, 38, 40, 43) .
Interleukin 10 is one of the most important anti-inflammatory cytokines known to suppress inflammation in mucosa (44) . It is produced mainly by macrophages, dendritic cells, Th2
and Treg cells (45) . We found significant increment of IL-10 in feces of patients with advanced endoscopic score (Figure 4 ), and this trend was detected in patients with higher clinical and total Mayo score (did not reach statistical significance). Based on our results, we believe that relatively enhanced fecal level of IL-10 in patients with severe UC is way to compensate intense inflammation and enhanced type 1 and type 17 immune response.
Interleukin 33 presents an alarmin and cytokine that plays role in polarization of immune response toward type 2 (46) . Soluble ST2 is decoy receptor for IL-33 (24) . Increased systemic values of sST2 have been detected in patients with chronic inflammatory diseases (47, 48) and correlate with disease severity (49) . Serum sST2 is proposed as potential biomarker of UC activity (49) . Our goal was to determinate whether fecal sST2 correlates with the severity of UC. We demonstrate, for the first time, significantly increased fecal level of sST2 in patients with more severe stage of UC (higher endoscopic, clinical and total Mayo score, respectively; Figure 5A ). Moreover, fecal sST2 was significantly increased in patients with intense cript destruction, erosion of the mucous membranes, architectural changes, neutrophil and eosinophil infiltration, respectively ( Figure 5B ). Also, it has been demonstrated that fecal sST2 correlates closely with the endoscopic, clinical and total Mayo score, as well as with histo-pathological parameters of affected tissue, and might be used to evaluate the severity of UC (Table 2 ). This observation is in line with previous reports indicating direct association between systemic sST2 and endoscopic score of UC as well as histopathological stage (49) . To our knowledge, this is the first study revealing direct association between fecal sST2 and the degree of endoscopic, clinical and histopathological activity of UC. Further in this study, we envisage the possible role of fecal sST2 as a biomarker in preceding disease severity and progression. Analysis of Receiver Operating Characteristic (ROC) curves of sST2 and disease parameters revealed that sST2 could predict advanced endoscopic and clinical score, at good sensitivity and specificity. According to our findings, fecal sST2 could be a valuable marker for UC severity and activity. The best cutoff point for sST2 concentration was obtained at a threshold of 624,0 pg/g, predicting active disease ( Figure 5 ).
Another novel finding in this study is strong positive correlation between IL-17 and sST2 in feces of UC patients ( Table 2 ). Both biomarkers correlate closely with parameters of disease severity. Little is known about IL-17/sST2 relation. Recent studies of inflammatory diseases, demonstrate that IL-33 suppresses type 17 immune response and subsequent production of IL-17 (50, 51) . Taken together, enhanced local values of sST2 can neutralize and reduce concentration of present IL-33 and thus suppress IL-33 inhibition of IL-17.
CONCLUSION
In summary, increased local values of sST2, reflected trough higher fecal concentration, in UC patients with higher endoscopic, clinical and total Mayo score, as well as histopathological parameters of affected tissue may be considered as a sign of the disease progression and, consequently, of a poor prognosis for patients. Increment of sST2 may facilitate IL-17 production, via IL-33 reduction, implicating on immunomodulatory role of sST2 in enhancing ongoing proinflammatory processes. Furthermore, the fecal values of sST2 can be used as a valuable marker for UC severity. These observations support the possible role of fecal sST2 as activity marker of UC and its potential use as therapeutic target.
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